The main advancement in this setting has been the development of monoclonal antibodies and multitarget tyrosine-kinase inhibitors (TKI) that inhibit tumor growth and angiogenesis through the vascular endothelial growth factor (VEGF) pathway (e.g., bevacizumab, axitinib, lenvatinib, cabozantinib and sunitinib) [1]. The gene discussed is VEGFA; the disease is neoplasm.